Betamethasone Sodium Phosphate Ph. Eur

• Phase 2 Study of ZN‑c3 in High-Grade Serous Ovarian Cancer Recruiting
  2022-502983-19-00 Phase II 5 countries K-Group Beta Inc.
• JAKAHDI - JAK inhibitors in acquired hemophagocytic syndrome in the ICU Recruiting
  2023-504513-77-00 Phase II 1 country Assistance Publique Hopitaux De Paris
• A clinical study to compare MK-2870 with pembrolizumab to pembrolizumab alone in people with lung cancer (MK-2870-007) Recruiting
  2023-503376-24-00 Phase III 9 countries Merck Sharp & Dohme LLC
• Expression-linked and R-ISS-adapted stratification for first line therapy in multiple myeloma patients (ELIAS) Recruiting
  2022-500453-16-00 Phase II 1 country University Medical Centre Schleswig-Holstein
• The DEXA-PSYCH Study: Dexamethasone Repurposing for Moderate to Severe Depression - A Double-Blind, Randomized, Parallel-Group, Placebo-Cont… Recruiting
  2022-501428-45-00 Phase III 1 country Region Hovedstadens Psykiatriske
• MK-2870 versus Chemotherapy in Previously Treated or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) with EGFR Mutations or Other … Ended
  2023-503539-16-00 Phase III 7 countries Merck Sharp & Dohme LLC
• A Phase 3 Study of Front‑line Platinum Doublet Therapy With Sotorasib Versus Pembrolizumab in PD-L1 Negative KRAS p.G12C Positive Advanced/M… Ended
  2022-501863-41-00 Phase III 17 countries Amgen Inc.
• A Phase 3, Multicenter, Randomized, Open Label Study of Venetoclax and Dexamethasone Compared with Pomalidomide and Dexamethasone in Subject… Ended
  2023-506112-40-00 Phase III 7 countries AbbVie Deutschland GmbH & Co. KG
• A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell … Ended
  2022-501259-10-00 Phase II 7 countries Kite Pharma Inc.
• A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell … Ended
  2022-501260-18-00 Phase II 7 countries Kite Pharma Inc.
• A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell Malignancie… Ended
  2022-501261-46-00 Phase II 7 countries Kite Pharma Inc.
• A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell … Ended
  2022-501262-21-00 Phase II 7 countries Kite Pharma Inc.
• A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) with VELCADE, Lenalidomide, and Dexamet… Ended
  2023-507312-13-00 Phase III 6 countries Janssen - Cilag International
• A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma Ended
  2023-505169-10-00 Phase II 1 country Kite Pharma Inc.

Showing 1–14 of 14 trials